Cerebral Microbleeds Load and Long-Term Outcomes in Minor Ischemic Stroke.

Abstract Background and Purpose The association between the cerebral microbleed (CMB) count and outcomes in ischemic stroke has not been fully clarified. The aim of this study was to investigate the relationship between the CMBs count and functional outcomes in patients with a minor ischemic stroke treated with antiplatelet therapy Methods Non-cardiogenic minor ischemic stroke (NIHSS score  4), and their clinical outcomes were compared. A poor outcome was defined as a modified Rankin scale (mRS) score of 3–6 90 days after symptom onset. Logistic regression analysis was performed to evaluate whether the CMBs count contributes to poor outcomes with well-known risk factors such as age, NIHSS score on admission, ischemic stroke recurrence, large artery atherosclerosis stroke subtype, and DWMHs. Results A total of 240 patients were enrolled, and their pre mRS scores were matched based on CMB presence. A higher burden of CMBs was linearly correlated with the incidence of poor outcomes (4% in the absent group, 8% in the 1 CMB group, 13% in the 2–4 CMB group, and 20% in the > 4 CMB group, P = 0.002). Multivariate logistic regression analysis showed that CMBs count was one of the independent factor associated with poor outcomes (odds ratio 1.07, 95% confidence interval 1.02–1.12, P = 0.003). Conclusion The CMBs count contributes independently to poor outcomes in minor ischemic stroke patients treated with antiplatelet therapy.